Antiemetics: American Society of Clinical Oncology clinical practice guideline update

Journal of Clinical Oncology

Volumn 29, Issue 31, 2011, Pages 4189-4198

  Basch, Ethan ^a   Prestrud, Ann Alexis ^d   Hesketh, Paul J ^e   Kris, Mark G ^a   Feyer, Petra C ^j   Somerfield, Mark R ^d   Chesney, Maurice ^b   Clark Snow, Rebecca Anne ^f   Flaherty, Anne Marie ^a   Freundlich, Barbara ^b   Morrow, Gary ^c   Rao, Kamakshi V ^g   Schwartz, Rowena N ⁱ   Lyman, Gary H ^h  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b University of Rochester Cancer Center ^*

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^e LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^f Lawrence Memorial Hospital   (United States)

^g UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^h DUKE UNIVERSITY   (United States)

ⁱ JOHNS HOPKINS HOSPITAL   (United States)

^j Vivantes Clinic of Radiooncology and Nuclear Medicine   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTHRACYCLINE; ANTIEMETIC AGENT; APREPITANT; AZACITIDINE; BENDAMUSTINE; CARBOPLATIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DAUNORUBICIN; DEXAMETHASONE; DOLASETRON MESILATE; DOXORUBICIN; GRANISETRON; IDARUBICIN; METOCLOPRAMIDE; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; PALONOSETRON; PROCHLORPERAZINE; SEROTONIN 3 ANTAGONIST; STREPTOZOCIN; TROPISETRON; UNINDEXED DRUG;

AMERICAN SOCIETY OF CLINICAL ONCOLOGY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; DRUG EFFICACY; DRUG FORMULATION; HEALTH CARE DISPARITY; HUMAN; MEDICAL SOCIETY; NAUSEA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT RESPONSE; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFUSIONS, INTRAVENOUS; ISOQUINOLINES; MORPHOLINES; NAUSEA; QUESTIONNAIRES; QUINUCLIDINES; RADIOTHERAPY; RECEPTORS, NEUROKININ-1; SEROTONIN ANTAGONISTS; VOMITING;

EID: 80755126820     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.34.4614     Document Type: Article

References (41)

1. Gralla RJ, Osoba D, Kris MG, et al.: Recommendations for the use of antiemetics: Evidencebased, clinical practice guidelines-American Society of Clinical Oncology. J Clin Oncol 17:2971-2994, 1999 (Pubitemid 29415258)
2. Kris MG, Hesketh PJ, Somerfield MR, et al.: American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. J Clin Oncol 24:2932-2947, 2006 (Pubitemid 46630595)
3. Grunberg SM, Chua DT, Maru A, et al.: Phase III randomized double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 28:641s, 2010 (suppl; abstr 9021)
4. Herrington JD, Jaskiewicz AD, Song J: Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer 112:2080-2087, 2008 (Pubitemid 351574085)
5. Hoshi E, Takahashi T, Takagi M, et al.: Aprepitant prevents chemotherapy-induced nausea and vomiting in Japanese cancer patients receiving highdoes cisplatin: A multicenter randomized, doubleblind, placebo-controlled study. 20th Anniversary International MASCC/ISOO Symposium, St Gallen, Switzerland, June 27-30, 2007 (abstr P-20)
6. Navari R, Gray S, Kerr A: Olanzapine versus aprepitant for the prevention of chemotherapyinduced nausea and vomiting (CINV): A randomized trial. 2010 MASCC/ISOO Symposium, Vancouver, British Columbia, Canada, June 24-26, 2010 (abstr 02-010)
7. Yeo W, Mo FK, Suen JJ, et al.: A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Breast Cancer Res Treat 113:529-535, 2009
8. Grunberg S, Chua D, Maru A, et al.: Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: Randomized, double-blind study protocol-EASE. J Clin Oncol 29:1495-1501, 2011
9. Hesketh PJ, Kris MG, Grunberg SM, et al.: Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103-109, 1997 (Pubitemid 27020563)
10. Billio A, Morello E, Clarke MJ: Serotonin receptor antagonists for highly emetogenic chemotherapy in adults. Cochrane Database Syst Rev 1:CD006272, 2010
11. Saito M, Aogi K, Sekine I, et al.: Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: A double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10:115-124, 2009
12. Jordan K, Hinke A, Grothey A, et al.: A metaanalysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer 15:1023-1033, 2007 (Pubitemid 47340963)
13. Ho CL, Su WC, Hsieh RK, et al.: A randomized, double-blind, parallel, comparative study to evaluate the efficacy and safety of ramosetron plus dexamethasone injection for the prevention of acute chemotherapy-induced nausea and vomiting. Jpn J Clin Oncol 40:294-301, 2010
14. Aapro MS, Grunberg SM, Manikhas GM, et al.: A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17:1441-1449, 2006 (Pubitemid 44400384)
15. Yu Z, Liu W, Wang L, et al.: The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: A phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial. Support Care Cancer 17:99-102, 2009
16. Aapro M, Fabi A, Nole F, et al.: Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 21:1083-1088, 2010
17. Rapoport BL, Jordan K, Boice JA, et al.: Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: A randomized, double-blind study. Support Care Cancer 18:423-431, 2010
18. Celio L, Frustaci S, Denaro A, et al.: Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: A randomized, multicenter, phase III trial. Support Care Cancer 19:1217-1225, 2011
19. Tan L, Liu J, Liu X, et al.: Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 28:131, 2009
20. Ryan JL, Heckler C, Dakhil SR, et al.: Ginger for chemotherapy-related nausea in cancer patients: A URCC CCOP randomized, double-blind, placebocontrolled clinical trial of 644 cancer patients. J Clin Oncol 27:485s, 2009 (suppl; abstr 9511)
21. Ezzo JM, Richardson MA, Vickers A, et al.: Acupuncture-point stimulation for chemotherapyinduced nausea or vomiting. Cochrane Database Syst Rev 2:CD002285, 2006
22. Phillips RS, Gopaul S: Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood. Cochrane Database Syst Rev 9:CD007786, 2010
23. Gore L, Chawla S, Petrilli A, et al.: Aprepitant in adolescent patients for prevention of chemotherapyinduced nausea and vomiting: A randomized, doubleblind, placebo-controlled study of efficacy and tolerability. Pediatr Blood Cancer 52:242-247, 2009
24. Sepúlveda-Vildósola AC, Betanzos-Cabrera Y, Lastiri GG, et al.: Palonosetron hydrochloride is an effective and safe option to prevent chemotherapyinduced nausea and vomiting in children. Arch Med Res 39:601-606, 2008 (Pubitemid 352033608)
25. Giralt S, Mangan K, Maziarz R, et al.: Palonosetron (PALO) for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose melphalan prior to stem cell transplant (SCT). J Clin Oncol 26:531s, 2008 (suppl; abstr 9617)
26. Stiff P, Fox-Geiman M, Kiley K, et al.: Aprepitant vs. placebo plus oral ondansetron and dexamethasone for the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to hematopoietic stem cell transplantation: A prospective, randomized doubleblind phase III trial. Blood 114:2267, 2009 (abstr)
27. Herrstedt J, Sigsgaard TC, Nielsen HA, et al.: Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy. Support Care Cancer 15:417-426, 2007 (Pubitemid 46697012)
28. Boccia RV, Gordan LN, Clark G, et al.: Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: A randomized, double-blind, phase III study. Support Care Cancer [epub ahead of print on September 12, 2010]
29. Gralla RJ, Roila F, Tonato M, et al.: MASCC/ ESMO antiemetic guideline 2010. http://data.member clicks.com/site/mascc/MASCC-Guidelines-English- 2010.pdf
30. Wong RK, Paul N, Ding K, et al.: 5- Hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: A placebocontrolled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19). J Clin Oncol 24:3458-3464, 2006 (Pubitemid 46638904)
31. Pectasides D, Dafni U, Aravantinos G, et al.: A randomized trial to compare the efficacy and safety of antiemetic treatment with ondansetron and ondansetron zydis in patients with breast cancer treated with high-dose epirubicin. Anticancer Res 27:4411-4417, 2007
32. US Food and Drug Administration: Drug information on oral palonosetron. http://www.accessdata .fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction= Search.DrugDetails
33. Grunberg S, Voisin D, Zufferli M, et al.: Oral palonosetron is as effective as intravenous palonosetron: A phase III dose ranging trial in patients receiving moderately emetogenic chemotherapy. Presented at the 14th European Conference of Clinical Oncology, Barcelona, Spain, September 23-27, 2007
34. Basch E: The missing voice of patients in drug-safety reporting. N Engl J Med 362:865-869, 2010
35. National Cancer Institute: Patient-Reported Outcomes version of the CTCAE (PRO-CTCAE). https://wiki.nci.nih.gov/display/PROCTCAE/Patient- Reported+Outcomes+version+of+the+CTCAE+%28PRO-CTCAE%29
36. US Cancer Statistics Working Group: United States cancer statistics: 1999-2002 Incidence and mortality Web-based report. http://apps.nccd.cdc .gov/uscs/
37. American Cancer Society: Cancer Facts and Figures for African Americans 2005-2006. Atlanta, GA, American Cancer Society, 2005
38. Mead H, Cartwright-Smith L, Jones K, et al.: Racial and Ethnic Disparities in U.S. Health Care: A Chartbook. New York, NY, The Commonwealth Fund, 2008
39. Ries LAG, Eisner MP, Kossary CL, et al.: SEER Cancer Statistics Review 1973-1997. Bethesda, MD, National Cancer Institute, 2000
40. Hickok JT, Roscoe JA, Morrow GR, et al.: Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: A University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer 97:2880-2886, 2003 (Pubitemid 36605158)
41. US Food and Drug Administration: Guidance for industry: Patient-reported outcome measures-Use in medical product development to support labeling claims. http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/UCM193282.pdf